Alpha Emitters Market Share, Size, Trends, Industry Analysis Report, By Type of Radionuclide (Radium, Actinium, Lead, Bismuth, and Others); By Application; By Region; Segment Forecast, 2023- 2032

Alpha Emitters Market Share, Size, Trends, Industry Analysis Report, By Type of Radionuclide (Radium, Actinium, Lead, Bismuth, and Others); By Application; By Region; Segment Forecast, 2023- 2032

The global alpha emitters market size is expected to reach USD 1,464.04 million by 2032, according to a new study by Polaris Market Research. The report “Alpha Emitters Market Share, Size, Trends, Industry Analysis Report, By Type of Radionuclide (Radium, Actinium, Lead, Bismuth, and Others); By Application; By Region; Segment Forecast, 2023- 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The rapid increase in awareness regarding the potential benefits of the targeted alpha emitter and the surge in the number of patients with several types of cancers like ovarian cancer, pancreatic cancer, melanoma, and lymphoma, coupled with the rising usage of alpha therapy due to its exceptionally high cell-killing ability, are among the prominent factors influencing the global market growth.

The rapid development of new targeting strategies that deliver alpha emitters specifically to cancer cells, which can be achieved by conjugating alpha-emitting isotopes with specific targeting molecules such as antibodies, peptides, or small molecules, enabling more precise delivery of the radiation dose to cancer cells while sparing healthy tissues, has been further creating lucrative growth opportunities soon. For instance, in June 2022, Alpha Tau Medical developed ‘Alpha DaRT” and enrolled 1st patient in its feasibility study to evaluate neo-adjuvant therapy for patients who have prostate cancer.

The growing penetration of automation as an important technological development in alpha emitters, particularly in the production of radiopharmaceuticals, has been pushing the market forward. The use of automated systems for labeling molecules with alpha emitters has made the production of radiopharmaceuticals faster and more efficient, allowing for larger-scale production and lower costs, due to which patients would be able to get access to these therapies more easily or conveniently.

Furthermore, researchers worldwide are exploring the use of combination therapies that combine alpha emitters with other cancer treatments, such as chemotherapy, immunotherapy, or radiation therapy, that could potentially enhance the efficacy of cancer treatments and reduce side effects.

Alpha Emitters Market Report Highlights

Radium segment accounted for largesrt market share in 2022, which is mainly driven by rising penetration as a superior cancer treatment due to beneficial properties like minimizing the narrow toxicity

Ovarian cancer segment is projected to grow at healthy CAGR during the anticipated period, mainly due to increasing new cases worldwide and adoption as an effective alternative to ovarian carcinoma

North America region led the industry market with substantial market share in 2022, owing to presence of several favorable government regulations and highly developed healthcare infrastructure across the region

The global key market players include IBA Radiopharma Solution, Telix Pharmaceuticals, Novartis, Fusion Pharmaceuticals, Orano Group, Cardinal Health, and Bayer

Polaris Market Research has segmented the alpha emitters market report based on type of radionuclide, application, and region:

Alpha Emitters, Type of Radionuclide Outlook (Revenue - USD Million, 2019 - 2032)

Radium

Actinium

Lead

Bismuth

Others

Alpha Emitters, Application Outlook (Revenue - USD Million, 2019 - 2032)

Pancreatic Cancer

Ovarian Cancer

Prostate Cancer

Lymphoma

Melanoma

Bone Metastasis

Others

Alpha Emitters, Regional Outlook (Revenue - USD Million, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa